Rapid exacerbation of bilateral hip osteoarthritis induced by immune checkpoint inhibitor therapy: A case report
Open Access
- 6 January 2026
- journal article
- Published by Oxford University Press (OUP) in Modern Rheumatology Case Reports
- Vol. 10 (1)
Abstract
Immune checkpoint inhibitors (ICIs) have revolutionised cancer therapy but are associated with immune-related adverse events, including musculoskeletal symptoms. We report a case of rapid exacerbation of bilateral hip osteoarthritis (OA) induced by nivolumab. A 56-year-old woman with a history of developmental hip dysplasia and malignant melanoma was treated with nivolumab. Following nivolumab administration, she developed severe bilateral hip pain and polyarthralgia, necessitating drug discontinuation. Despite cessation of the ICI, her symptoms persisted, accompanied by elevated C-reactive protein levels. Imaging showed end-stage OA with joint space narrowing and increased 18F-fluorodeoxyglucose uptake in both hip joints. She underwent staged bilateral total hip arthroplasty. Intraoperative pathology showed marked synovial hyperplasia. Immunohistochemical analysis showed diffuse positivity for CD68, tumour necrosis factor-α, interleukin-6, programmed cell death protein 1, and programmed death-ligand 1, findings consistent with an immune-mediated inflammatory process superimposed on degenerative changes. Postoperatively, her hip pain and associated symptoms gradually improved, accompanied by normalisation of inflammatory markers during follow-up. Histological evidence suggests that programmed cell death protein 1/programmed death-ligand 1 blockade may locally amplify inflammation within the osteoarthritic joint. Clinicians must be vigilant regarding the potential for ICIs to rapidly worsen underlying joint disease, warranting timely surgical intervention when conservative management fails.Keywords
This publication has 18 references indexed in Scilit:
- OsteoarthritisThe Lancet, 2025
- EULAR points to consider for the diagnosis and management of rheumatic immune-related adverse events due to cancer immunotherapy with checkpoint inhibitorsAnnals of the Rheumatic Diseases, 2021
- Nivolumab-induced synovitis is characterized by florid T cell infiltration and rapid resolution with synovial biopsy-guided therapyJournal for ImmunoTherapy of Cancer, 2020
- Immune-related adverse events of checkpoint inhibitorsNature Reviews Disease Primers, 2020
- Five-Year Survival with Combined Nivolumab and Ipilimumab in Advanced MelanomaNew England Journal of Medicine, 2019
- Rheumatic Syndromes Associated With Immune Checkpoint Inhibitors: A Single‐Center Cohort of Sixty‐One PatientsArthritis & Rheumatology, 2019
- Rheumatic diseases associated with immune checkpoint inhibitors in cancer immunotherapyModern Rheumatology, 2018
- Checkpoint Inhibitors: Applications for AutoimmunityCurrent Allergy and Asthma Reports, 2017
- Is autoimmunity the Achilles' heel of cancer immunotherapy?Nature Medicine, 2017
- Immune-related adverse events with immune checkpoint blockade: a comprehensive reviewEuropean Journal of Cancer, 2016